Latest Breaking News On - Global burden - Page 1 : comparemela.com

More people with type 1 diabetes are living longer, but global inequalities still exist

The number of people aged 65 and older with type 1 diabetes increased from 1.3 million in 1990 to 3.7 million in 2019, while death rates fell 25% from 4.7 per 100,000 population in 1990 to 3.5 in 2019, finds an analysis of data from over 200 countries and regions published in The BMJ.

United kingdomUnited statesGlobal burdenRisk factors studyNorth americaSaharan africaBritish medical journal

Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study

Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

Jing zhangUnited statesChenye jinKaijie yangZhao sunTingting liuXue yangYongze liBing maChina postdoctoral science foundationNational natural science foundation of chinaGlobal burdenRisk factors studyNorth americaSaharan africaNational natural science foundation

Adults with Sickle Cell Report Poor Health-Related Quality of Life Scores

Based on the 36-item Short Form Survey questionnaire, adults with SCD in France report low physical and mental health summary scores.

Issifou yayaItem short form surveyPadrinos health literacyFront public healthOutcomes researchPatient reported outcomes researchPhysical component summaryMental component summaryPhysical functioningGeneral healthCell diseaseGlobal burdenDisease studyPerceived stigmaSickle cellWestj nurs

Australians Living Longer, But In Need Of More Support

Photo credit: Matthias Zomer A study of pre-COVID-19 health data found Australians over 70 were living longer, but their impact on the

University of adelaideSouth australiaLilianag ciobanuScottr clarkLancet regional healthPsychiatry discipline associate professor scottGlobal burdenAssociate professor

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date .

United kingdomUnited statesNational institute of diabetesInternational diabetes federationDrug administrationUs centers for diseaseNational diabetes statisticsEuropean medicines agencyCenters for diseaseExecutive vice presidentBiopharmaceuticals business unitDisease controlNew england journalMedicine evidenceMycotic infectionsCommon adverse reactions